Improving clinical reality in chronic obstructive pulmonary disease economic modelling: Development and validation of a micro-simulation approach

PharmacoEconomics

Volumn 31, Issue 2, 2013, Pages 151-161

  Asukai, Yumi ^a   Baldwin, Michael ^b   Fonseca, Tiago ^a   Gray, Alastair ^d   Mungapen, Laura ^a   Price, David ^c  

^a IQVIA   (United States)

^b NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TIOTROPIUM BROMIDE;

ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PATHWAY; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DISEASE SIMULATION; DYSPNEA; ECONOMIC EVALUATION; EXTERNAL VALIDITY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEALTH CARE POLICY; HEALTH STATUS; HUMAN; LUNG FUNCTION; MONTE CARLO METHOD; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TEACHING; TREATMENT DURATION; UNCERTAINTY; VALIDATION PROCESS;

ADULT; AGED; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMIC; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84876237493     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-012-0016-3     Document Type: Article

References (37)

1. World Health Organization. Chronic obstructive pulmonary disease (COPD): fact sheet no. 315. Geneva: WHO: 2011.
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of COPD. Bethesda: GOLD; 2011.
3. Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest. 2000;117(2 Suppl):5S-9S.
4. National Clinical Guideline Centre. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. London: NICE; 2010.
5. Rutten-van Molken MP, Goossens L. Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease. Pharmacoeconomics. 2012;30(4):271-302.
6. Starkie HJ, Briggs AH, Chambers MG. Pharmacoeconomics in COPD: lessons for the future. Int J Chron Obstruct Pulm Dis. 2008;3(1):71-88.
7. Higgins JPT GS. Cochrane handbook for systematic reviews of interventions [version 5.0.2]. The Cochrane Collaboration; 2009.
8. Buxton MJ, Drummond MF, Van Hout BA, Prince RL, Sheldon TA, Szucs T, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ. 1997;6(3):217-27.
9. Neyt M, Devriese S, Thiry N, Van den BA. Tiotropium's cost-effectiveness for the treatment of COPD: a cost-utility analysis under real-world conditions. BMC Pulm Med. 2010;10:47.
10. Menn P, Leidl R, Holle R. A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease. Pharmacoeconomics. 2012;30(9):825-40.
11. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13(4):322-38.
12. Borg S, Ericsson A, Wedzicha J, Gulsvik A, Lundback B, Donaldson J, et al. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health. 2004;7(2):153-67.
13. Hoogendoorn M, Rutten-van Molken MP, Hoogenveen R, van Genugten M, Buist A, Wouters E, et al. A dynamic population model of disease progression in COPD. Eur Resp Med. 2005;26(2):223-33.
14. Oostenbrink JB, Rutten-van Molken MP, Monz BU, FitzGerald J. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health. 2005;8(1):32-46.
15. Sin D, Golmohammadi K, Jacobs P. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. Am J Med. 2012;116(5):325-31.
16. Spencer M, Briggs AH, Grossman RF, Rance L. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics. 2005;23(6):619-37.
17. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-89.
18. Tashkin D, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. New Engl J Med. 2008;359(15):1543-54.
19. Aaron SD, Ramsay T, Vandemheen K, Whitmore GA. A threshold regression model for recurrent exacerbations in chronic obstructive pulmonary disease. J Clin Epidemiol. 2010;63(12):1324-31.
20. Mapel DW, Schum M, Lydick E, Marton JP. A new method for examining the cost savings of reducing COPD exacerbations. Pharmacoeconomics. 2010;28(9):733-49.
21. Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ. 2006;15(12):1295-310.
22. Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65(6):473-9.
23. Donohue JF, Fogarty C, Lotvall J, Mahler DA, Worth H, Yorgancioglu A, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182(2):155-62.
24. Feldman G, Siler T, Prasad N, Jack D, Piggott S, Owen R, et al. Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med. 2010;8(10):11.
25. Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
26. Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med. 2000;161(2 Pt 1):381-90.
27. Hoogendoorn M. Economic impact of COPD: empirical and model-based studies on the cost-effectiveness of treatment options [dissertation]. Rotterdam: Erasmus University; 2011.
28. Jones RC, Donaldson GC, Chavannes NH, Kida K, Jackson-Spillmann M, Harding S, et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med. 2009;180(12):1189-95.
29. Office of National Statistics. UK interim life tables. Newport: ONS; 2011.
30. Rutten-van Molken MP, Oostenbrink JB, Miravitlles M, Monz BU. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ. 2007;8(2):123-35.
31. Richards DW, Cournand A, Rappaport I. Relation of the regulatory mechanism of respiration to clinical dyspnea. Proc Natl Acad Sci USA. 1935;21(7):498-501.
32. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984;85(6):751-8.
33. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med. 1991;85(Suppl. B):25-31.
34. Starkie HJ, Briggs AH, Chambers MG, Jones P. Predicting EQ-5D values using the SGRQ. Value Health. 2011;14(2):354-60.
35. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic health evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
36. Lundback B, Eriksson B, Lindberg A, Ekerljung L, Muellerova H, Larsson LG, et al. A 20-year follow-up of a population study-based COPD cohort: report from the obstructive lung disease in Northern Sweden studies. COPD. 2009;6(4):263-71.
37. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. New Engl J Med. 2010;363(12):1128-38.